Quick Answer
Stoke Therapeutics, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
Stoke Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.12 | +92.7% |
| 2024 | -$1.65 | +30.7% |
| 2023 | -$2.38 | +8.5% |
| 2022 | -$2.60 | -11.1% |
| 2021 | -$2.34 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.65 | -38.3% | -62.5% |
| June 30, 2025 | -$0.40 | +13.0% | -121.1% |
| March 31, 2025 | $1.90 | +433.3% | +504.3% |
| September 30, 2024 | -$0.47 | +14.5% | -2.2% |
| June 30, 2024 | -$0.46 | +33.3% | +19.3% |
| March 31, 2024 | -$0.57 | -7.5% | -3.6% |
| September 30, 2023 | -$0.55 | +16.7% | +20.3% |
| June 30, 2023 | -$0.69 | -9.5% | -30.2% |
- Stoke Therapeutics, Inc. showed an increase of +92.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Stoke Therapeutics, Inc.’s diluted eps has grown by 94.9% (from $2.34 per share (loss) to $0.12 per share (loss)).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: